Table 1. Baseline characteristics.
| Characteristics | Study population (n=72) | |
|---|---|---|
| Age (yr) | 62.5±13.0 | |
| Menopausal status | ||
| No | 16 (22.2) | |
| Yes | 51 (70.9) | |
| NA | 5 (0.7) | |
| FIGO stage | ||
| IIIB | 9 (12.5) | |
| IIIC | 55 (76.4) | |
| IVA | 1 (1.4) | |
| IVB | 7 (9.7) | |
| ECOG performance status | ||
| 0 | 26 (36.1) | |
| 1 | 29 (40.3) | |
| 2 | 2 (2.8) | |
| NA | 15 (20.8) | |
| Type of surgical approach | ||
| Primary cytoreduction | 53 (73.6) | |
| IDS after failure of primary attempt | 15 (20.8) | |
| IDS | 4 (5.5) | |
| RD at primary surgical attempt (n=68) | ||
| Complete | 44 (64.7) | |
| Optimal | 49 (7.2) | |
| Non-optimal | 19 (27.9) | |
| RD at IDS (n=19) | ||
| Complete | 7 (36.8) | |
| Optimal | 6 (31.6) | |
| Non-optimal | 6 (31.6) | |
| Recurrence | ||
| No | 50 (69.4) | |
| Yes | 18 (25.0) | |
| NA | 4 (5.6) | |
Data are reported as mean±standard deviation or as numbers and percentage.
FIGO, International Federation of Gynecology and Obstetrics; ECOG, Eastern Cooperative Oncology Group; IDS, interval debulking surgery; NA, not available; RD, residual disease.